HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

12th Edition of International Conference on Neurology and Brain Disorders

October 20-22, 2025

October 20 -22, 2025 | Orlando, Florida, USA
INBC 2024

NF1-associated gliomas: Antioxidant treatments and spastin inactivation as possible therapeutic approaches

Speaker at Neuroscience Conference - Cinzia Rinaldo
IBPM-CNR, Italy
Title : NF1-associated gliomas: Antioxidant treatments and spastin inactivation as possible therapeutic approaches

Abstract:

Neurofibromatosis type 1 (NF1) is the most common tumor predisposition syndrome and glioma is one of the prevalent tumors associated with it. Gliomagenesis in NF1 patients results in a heterogeneous spectrum of neoplasms, ranging from low- to high-grade, that can occur throughout their entire lifespan.

The NF1 tumor suppressor gene encodes neurofibroimin, a GTPase-activating protein that acts as a negative regulator of the RAS oncoprotein. Loss of neurofibromin expression, as observed in NF1.associated tumors, is predicted to increase cell growth and survival through hyperactivation of RAS. Neurofibromin is also involved in regulating the cytoskeleton and cell motility. The ability of glioma cells to migrate long distances through the brain is a major obstacle to effective treatment of this tumor.

The microtubule (MT)-severing protein spastin is an AAA ATPase enzyme controlling MT dynamics and lipid droplet (LD) trafficking and functions. Spastin plays key role in processes requiring active rearrangement of the cytoskeleton and membrane remodeling, such as cell proliferation and motility. Our observations indicate that spastin silencing or its inhibition, induced by the ATP competitive inhibitor spastazoline, reduces colony-forming capacity, single cell speed and migration ability in glioma cell models. We identified the molecular players involved in spastin-dependent LD behavior by mass spectrometry analyses. Automated cell imaging-based pipelines were developed to measure the number, size and distribution of LDs, as well as MT cytoskeleton organization, to investigate LD behavior and its crosstalk with migration. Furthermore, recent evidence supports the beneficial effect of antioxidants on the prevention and treatment of NF-1 associated tumors. Thus, the effects of antioxidant compounds in combination with spastin inhibition will be also analysed, opening the way to develop new therapeutic strategies for NF1-associated gliomas.

Audience Take Away Notes:

Our work aims to expand knowledge on the relationship between energy reserves (LD) and cell migration in the context of gliomas. It provides a practical solution for automatic cell-imaging analysis, particularly for the number of LDs and MT cytoskeletal organization. Additionally, we propose new therapeutic strategies based on the use of natural compounds.

Biography:

Dr. Rinaldo studied Biology at Federico II University of Naples and received her PhD from the same institution in 2002. She then joined Dr Soddu's research group at Regina Elena Cancer Institute (IRE) in Rome, Italy as a PostDoc, where she contributed to characterising a new pro-apoptotic regulator of the p53 oncosuppressor gene, the HIPK2 kinase. In 2011, she became a permanent researcher and started her own research group at IBPM-CNR in Rome, Italy. Currently, she is a senior researcher at the same institution, leading a group that studies the molecular mechanisms that control tumor growth and the response to anti-cancer treatments.

Watsapp